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1. Introduction 
Approximately 20 to 30 % of all breast cancer cases are classified as HER2/neu-positive 
(McCann et al. 1991). The overexpression the HER2 receptor tyrosine kinase is most 
commonly caused by a gene amplification and is associated with aggressive tumor behavior 
(Hynes & Stern 1994). Patients with HER2/neu overexpressing tumors have a significantly 
shorter time to relapse as well as a reduced overall survival rate compared to patients with 
normal HER2/neu expression levels (Berchuck et al. 1990; Slamon et al. 1989; Slamon et al. 
1987). The oncogenic properties of HER2/neu were first discovered in rat neuroblastoma 
(“neu”) as a tumor antigen related to epidermal growth-factor receptor (EGFR) (Schechter et 
al. 1984). The human homologue to neu was mapped to chromosome 17q21 and, because of 
its similarity to the human EGF receptor, named human EGF receptor 2 (HER2) (Coussens et 
al. 1985; King et al. 1985). Two more members of the HER family, namely HER3 and HER4, 
were subsequently identified (Kraus et al. 1989; Plowman et al. 1993). In this review we will 
discuss the altered metabolism and potential downstream effects found in breast cancer cells 
with increased HER2/neu expression. 
1.1 The HER family of receptor tyrosine kinases 
The HER family of receptors are found in a variety of tissues and interact with several EGF-
like ligands (Harris et al. 2003). HER2 plays an important role in human development, it has 
been detected in the nervous system, bone, muscle, skin, heart, lungs and intestinal 
epithelium (Coussens et al. 1985; Quirke et al. 1989). Deletion of HER2 in mice leads to 
embryonic lethality (Meyer & Birchmeier 1995). Upon ligand binding, the receptors either 
homo- or heterodimerize and transphosphorylate each other. This initiates downstream 
signaling cascades through a variety of adaptor proteins and second messengers resulting in 
cell cycle progression, proliferation and survival (Bazley & Gullick 2005; Alroy & Yarden 
1997). Even though HER2 does not bind any ligand by itself, it has been reported to display 
low affinity interactions with many, if not all, ligands in any given receptor heterodimer 
(Tzahar & Yarden 1998). It has been suggested that HER2 is the preferred dimerization 
partner for all the ligand-binding members of the HER family and that HER2 heterodimers 
are more active than their homodimeric counterparts (Yarden 2001), which might be due to 
enhanced recycling of HER2 receptor heterodimers to the cell surface (Lenferink et al. 1998). 
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This indicates that a disregulation of HER2 levels will lead to increased receptor 
dimerization and thus increased signaling. 
The expression levels of HER2 in malignant cells can be increased up to 100-fold compared 
to normal cells, resulting in as many as two million HER2 molecules per cell (Park et al. 
2006; Liu et al. 1992; Venter et al. 1987). This overexpression is most commonly caused by an 
amplification of the HER2 gene, which leads to increased transcription and protein 
synthesis. Experiments utilizing fluorescence in situ hybridization suggest that only about 
3 % of HER2 overexpressing breast cancers do not carry a corresponding gene amplification 
(Pauletti et al. 1996). The majority of HER2 overexpressing breast cancer cells have been 
shown to have 25-100 copies of the HER2 gene (Kallioniemi et al. 1992). This gene 
amplification and overexpression of the HER2 protein identifies a subset of the breast cancer 
disease which is found independent of disease stage. In fact, gene expression studies show 
that HER2 overexpressing tumors display a characteristic molecular pattern that is 
maintained as the cancer progresses, indicating that HER2 amplification is an early event in 
carcinogenesis (Weigelt et al. 2005; Perou et al. 2000). HER2 overexpression is found in 
almost half of all ductal carcinoma in situ (DCIS) that show no evidence of invasion but does 
not occur in benign breast disease (Allred et al. 1992; Park et al. 2006; Liu et al. 1992).  
1.2 Treatment of HER2/neu-positive breast cancer 
These advances in basic breast cancer research lead to the development of the first truly 
targeted cancer therapy agent, the humanized monoclonal antibody trastuzumab 
(Herceptin®, Genentech) (Carter et al. 1992). Herceptin was FDA approved in 1998 for the 
treatment of advanced metastatic breast cancer (Hortobagyi 2001). Possible mechanisms of 
action and the safety profile of trastuzumab are reviewed in Hudis et al. (2007). After initial 
success of using Herceptin in the clinic (Vogel et al. 2002), more and more reports about 
tumors developing Herceptin resistance were published (recently reviewed in Mukohara 
2011). Truncated HER2 receptors (p95HER2) lacking the extracellular domain, which is 
targeted by Herceptin, were identified in human breast tumors (Molina et al. 2002). This 
prompted the development of new, second generation targeted therapies like tyrosine 
kinase inhibitors, HSP90 inhibitors, inhibitors of PI3 kinase, new anti-HER2 antibodies as 
well as HER2-based vaccination strategies. These novel anti-HER2 strategies are reviewed in 
Mukohara (2011).  
Even though it has been almost 25 years since the discovery of HER2 as an identifier of a 
unique subset of breast cancers, we still have not conquered the disease with therapies 
directed against HER2. The ability of HER2 driven breast tumors to consistently develop 
resistance against therapies targeting HER2 underlines the importance of further research in 
this area. The underlying genetics associated with HER2 overexpression seem to be 
responsible for a more complex picture that is only hinted at by HER2 diagnostics. 
2. The genetics of HER2/neu-positive breast cancer 
Several studies in the past decade show that HER2 protein overexpression or gene 
amplification is not the only alteration in the breast cancer subtype denoted HER2 positive. 
Transcriptional profiling (meta-) analyses have demonstrated that a number of genes are 
commonly overexpressed along with HER2. At the beginning of this century, a specific gene 
expression signature was reported for HER2/neu-positive tumors and cell lines using DNA 
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microarrays as well as comparative genomic hybridization techniques (Pollack et al. 1999; 
Perou et al. 2000). Co-amplification of individual genes was reported as early as 1993 (Keith 
et al. 1993). A microarray based screen (probes for 217 ESTs on chromosome 17) by 
Kauraniemi et al. (2001) using 14 breast cancer cell lines identified seven transcripts as the 
minimal region of co-amplification with HER2.  
In a more extensive study, Bertucci et al. (2004) used a microarray platform with ~9000 
cDNA probes. The analysis of 213 different tumor samples as well as 16 breast cancer cell 
lines yielded a characteristic gene expression signature of 37 differentially expressed genes 
for HER2/neu-positive tumors/cell lines. According to this “HER2-Signature”, 29 genes 
were up- and 8 downregulated. Using this expression signature the group was able to 
predict the HER2 status of tumors with remarkable accuracy compared to the classical 
histologic classification methods (92.2% accurate compared to 85.9% for FISH and IHC). 
Seven of those 29 upregulated genes are located on chromosome 17q12, close enough to the 
HER2 gene locus to be candidates for co-amplification. Indeed, of these seven genes four 
were also part of the minimal region of co-amplification identified by Kauraniemi et al. 
(2001). The most striking targets in this “HER2 gene expression signature”, apart from 
HER2, are the peroxisome proliferator receptor binding protein (PBP) and NR1D1, a nuclear 
receptor for heme and regulator of adipogenesis as well as circadian rhythm. NR1D1 is also 
known as Rev-erb-alpha. Later studies confirmed the overexpression and co-amplification 
of these genes in HER2/neu-positive breast cancer (Arriola et al. 2008; Chin et al. 2006).  
Recently, an extensive RNAi-based screen by Kourtidis et al. (2010) evaluated 141 genes that 
were previously reported to be overexpressed in HER2/neu-positive breast cancers. 
Kourtidis et al. used shRNA constructs derived from a genome-wide shRNA library to 
transfect the well established HER2/neu-positive breast cancer cell line model BT474 and 
subsequently monitored changes in cell proliferation. The shRNA targets that resulted in the 
highest decrease of cell proliferation were confirmed by a second round of transfections. The 
most significant reduction in proliferation occurred after knockdown of HER2, indicating 
that the experimental approach was valid. Interestingly, knockdown of NR1D1 and PBP 
resulted in the third and fourth most significant reduction of cell proliferation which was 
found to be due to decreased viability. To confirm these results, SKBR3 and MDA-MB-361, 
both HER2/neu-positive cell lines, were transfected with the same constructs, resulting in a 
severe decrease of viability compared to control. Knockdown of these two targets in cell 
lines that do not carry the HER2 amplicon (breast cancer MCF7, MDA-MB-453, MDA-MB-
468, normal human mammary epithelial cells – HMEC – and human kidney HEK293 cells) 
was without effect. 
NR1D1 was first identified as an orphan nuclear receptor in 1989 (Miyajima et al. 1989). 
Since then it has been discovered that NR1D1 is a constitutive transcriptional repressor 
(Harding & M A Lazar 1995) and a nuclear receptor for heme, the binding of which actually 
enhances repression (Yin et al. 2007; Raghuram et al. 2007). NR1D1 is also an important 
regulator of the circadian rhythm. Circadian oscillations in gene expression are based on a 
24 hour time frame and are present throughout the animal kingdom (Panda et al. 2002). 
They allow the organism to anticipate changes in metabolic activity and food availability. 
The master clock is located in the suprachiasmatic nuclus (SCN) of the hypothalamus which 
is responsive to light. This master clock synchronizes peripheral clocks that have an 
important role in organ homeostasis. The circadian regulation allows for metabolic enzymes 
to be expressed at the appropriate times to avoid, for example, the simultaneous expression 
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of glycolytic and gluconeogenic enzymes (Duez & Staels 2009). Disruptions of circadian 
cycles have been linked to various diseases such as mental illness, metabolic syndrome and 
cancer (Gachon et al. 2004). The cycle of a peripheral clock starts when the two positive 
regulators BMAL1 and CLOCK heterodimerize and initiate transcription of their target 
genes. Among those targets are also negative regulators of BMAL1 and CLOCK 
transcription like NR1D1, which binds to their respective promoters and, by recruiting 
NCoR and HDAC3, represses transcription of BMAL1 and CLOCK (Yin and Lazar 2005). 
This creates a negative feedback loop resulting in oscillating levels of circadian rhythm 
regulatory proteins. NR1D1 also binds to its own promoter, thus repressing NR1D1 
transcription once a critical protein concentration is reached (Adelmant et al. 1996). NR1D1 
levels are high in metabolically active tissues including adipose tissue and liver (Lazar et al. 
1989). NR1D1 is required for adipocyte differentiation (Wang & Lazar 2008) and its 
overexpression enhances adipogenesis in 3T3-L1 adipocytes (Fontaine et al. 2003). This is 
particularly intriguing as Kourtidis et al. observed significant differences in the amount of 
stored neutral fats in HER2 overexpressing breast cancer cells compared to other breast 
cancer cells with normal HER2 expression levels as well as human mammary epithelial cells. 
HER2 overexpressors consistently showed higher fat content than other breast cancer cells. 
The peroxisome proliferator receptor-gamma binding protein (PBP) is a nuclear receptor co-
activator also called mediator complex subunit 1 (MED1). Other names include CRSP1, 
RB18A, TRIP2, CRSP200, DRIP205, DRIP230, TRAP220 and MGC71488. Throughout this text 
we will refer to it as PBP. PBP was first identified through a yeast-2-hybrid screen using 
PPARǄ as bait. It was capable of enhancing PPARǄ dependent transcription (Zhu et al. 
1997). Subsequently, PBP has been shown to be a critical component of the mediator 
complex, which is required for polymerase II mediated transcription (Kornberg 2005; Malik 
& Roeder 2005). Apart from binding to PPARǄ, PBP also interacts with various other nuclear 
receptors like PPARǂ, TRǃ, VDR, ERǂ, RARǂ, RXR and GR and is strongly expressed in the 
developing mouse embryo, suggesting an important role in cellular proliferation and 
differentiation (Viswakarma et al. 2010; Zhu et al. 1997). Indeed, a complete knockout of PBP 
in mice leads to embryonic lethality on day 11.5 (Zhu et al. 2000). In a carcinogenesis study 
using diethylnitrosamine followed by phenobarbital promotion, PBP null liver cells fail to 
undergo proliferation. All tumors that arise in mice carrying a conditional liver PBP 
knockout develop from cells that have retained PBP expression. This indicates that PBP is 
required for the development of hepatocellular carcinoma in mice (Matsumoto et al. 2010). 
Moreover, it has been shown that PBP is required for mammary gland development (Yuzhi 
Jia et al. 2005). 
The PPARs belong to the superfamily of nuclear receptors and typically regulate the 
transcription of genes associated with lipid metabolism (Desvergne & Wahli 1999). In fact, 
PPARǄ is required for adipocyte differentiation and NR1D1 is a transcriptional target of 
PPARǄ (Tontonoz et al. 1994; Fontaine et al. 2003). Indeed, Kourtidis et al. showed that 
knockdown of PBP results in decreased mRNA levels of NR1D1. Co-transfection of BT474 
cells with shRNAs targeting PBP and NR1D1 does not result in increased cell death, 
indicating that these two regulators work synergistically. Treatment of cells with a PPARǄ 
antagonist results in reduced message levels of NR1D1 and induces apoptosis in BT474 cells. 
The survival advantage caused by PBP and NR1D1 overexpression is independent of HER2 
overexpression as HER2 message levels do not change after NR1D1 knockdown. Instead, 
NR1D1 and PBP indirectly induce a lipogenic phenotype which results in increased fat 
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synthesis and storage. Disruption of this synthetic pathway results in HER2/neu-positive 
breast cancer cell apoptosis but does not affect HER2 negative cells. 
PPARǄ, PBP and NR1D1 are responsible for a markedly altered physiology in cells carrying 
the HER2 amplicon. These new co-amplified and overexpressed transcriptional regulators 
cooperatively change the metabolism of HER2/neu-positive breast cancer cells by inducing 
a unique, Warburg-like metabolism that is primed towards fat production. The next section 
will discuss this metabolism in detail. 
3. The altered metabolism of HER2/neu-positive breast cancer  
NR1D1, PBP and PPARǄ are required for adipogenesis and many of their transcriptional 
targets are related to lipid metabolism. Their unregulated overexpression in HER2/neu-
positive breast cancer causes a unique metabolic phenotype that relies on aerobic glycolysis 
and fatty acid synthesis for energy production and survival.  
Kourtidis et al. show that the amount of stored neutral fats is about 20-fold higher compared 
to human mammary epithelial cells and about 10-fold higher compared to HER2 negative 
breast cancer lines. Knockdown of PBP and NR1D1 results in a significant decrease of fat 
stores and overexpression of NR1D1 in immortalized, non-tumorigenic, MCF10A cells 
increases their fat content by about 4-fold compared to vector control. Further studies using 
fructose and galactose as alternative fuel sources indicate that it is not the amount of fat 
stores but the requirement for active fatty acid synthesis that is important for the survival of 
HER2/neu-positive breast cancer cells. While PBP and NR1D1 knockdown decreases fat 
stores and viability, similar decreases in fat stores through cell growth in fructose or 
galactose containing media did not alter viability in these cells. 
Investigation of transcript levels of potential downstream targets of PBP and NR1D1 
revealed significant changes in ATP-citrate lyase (ACLY), acetyl-CoA carboxylase ǂ 
(ACACA), fatty acid synthase (FASN) and fatty acid desaturase 2 (FADS2) mRNA levels 
after knockdown of either PBP or NR1D1. Indeed, shRNA mediated knockdown of ACLY, 
ACACA and FASN resulted in decreased viability in HER2/neu-positive breast cancer cells.  
Other studies have already shown a tight link between FASN and HER2. Overexpression of 
FASN in immortalized, non-tumorigenic HBL100 and MCF10A cells induces oncogenic 
properties and results in upregulation and activation of HER1 and HER2 (Vazquez-Martin 
et al. 2008). There is evidence that HER2 posphorylates FASN, which results in increased 
enzymatic activity. Blocking FASN phosphorylation and enzymatic activity by either 
lapatinib (HER2 specific tyrosine kinase inhibitor) or C75 (FASN inhibitor) suppressed 
invasion of SKBR3 and BT474 cells (Jin et al. 2010). 
In order to sustain this lipogenic phenotype, the cells are in constant demand of cofactors 
that are essential for glycolysis and fatty acid synthesis. Nicotinamide adenine dinucleotide 
(NAD+) is required to take up electrons from glucose and coenzyme A is required to transfer 
carbons from glucose to fatty acids. Once NAD+ is reduced to NADH the electrons need to 
be shuttled to NADPH so that they can be used in fatty acid synthesis. Two cytoplasmic 
enzymes are required for the formation of cytoplasmic NADPH. Malate dehydrogenase 
(MDH1) produces malate from oxaloacetate using NADH as a cofactor, whereas malic 
enzyme (ME1) cleaves malate to pyruvate and CO2 while reducing NADP+ to NADPH. ME1 
is the primary producer of cytoplasmic NADPH which can then be used for fatty acid 
synthesis. Knockdown of MDH1 and ME1 with shRNAs significantly reduced mRNA levels 
and cell viability in BT474 cells (Kourtidis et al. 2010). This represents a new physiological 
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alteration that is transcriptionally independent from the NR1D1 and PBP axis since 
knockdown of PBP does not change mRNA levels of MDH1 or ME1. The importance of fatty 
acid synthesis in this type of cancer is underscored by the finding that FASN inhibition 
reverses Herceptin resistance in SKBR3 cells (Vazquez-Martin et al. 2007).  
To date, there is not much known about the contribution of coenzyme A (CoA) metabolism 
to this lipogenic phenotype. One study reported that a PPARǂ agonist regulates CoA levels 
through the induction of pantothenate kinase 1ǂ (PanK1alpha), which catalyzes the rate-
limting step in CoA biosynthesis (Ramaswamy et al. 2004). The agonist used in this study is 
actually a pan-PPAR agonist (Krey et al. 1997), so there is a plausible connection between 
PPAR action and coenzyme A. Interestingly, overexpression of NR1D1 in MCF10A cells 
results in a 50% decrease of pantothenate levels compared to vector control, indicating 
increased substrate flux through pantothenate kinase (Baumann et al, unpublished data). 
Further studies are under way in our lab to determine how PBP and NR1D1 influence the 
metabolism of coenzyme A and vice versa.  
The amount of palmitate produced by HER2/neu-positive breast cancer cells would 
normally result in cytotoxicity and apoptosis but the overexpression of PBP and NR1D1 
allows for the neutralization of these toxic products by generating neutral triglycerides in a 
PPARǄ dependent fashion. This system is operating close to the limit, as addition of free 
palmitic acid results in ROS mediated cell death of HER2/neu-positive but not HER2 
negative breast cancer cells (Kourtidis et al. 2009). Metabolomic analysis of NR1D1 
overexpressing MCF10A cells shows a drastically altered metabolite profile (Baumann et al, 
unpublished data). Levels of pathway intermediates in glycolysis and TCA are decreased, 
whereas lipids and lipid progenitor molecules are markedly increased. Overall energy levels 
seem to decrease with NR1D1 overexpression as nucleotide triphosphate levels are low. 
Nucleotide precursors from the pentose phosphate shunt are increased, while NADPH 
levels are low. These data indicate that NR1D1 overexpression results in increased metabolic 
flux through glycolysis and the pentose phosphate shunt towards nucleotide precursors and 
lipids. Of course this type of metabolism has to be balanced by appropriate anaplerotic 
reactions or the flux towards fatty acids would quickly deplete the TCA cycle of 
oxaloacetate, the “acceptor”-molecule for acetyl-CoA generated from pyruvate. Many cancer 
cells in culture have been shown to utilize glutaminolysis to achieve this goal (Weinberg & 
Chandel 2009). While BT474 cells also require glutamine in the culture medium, 
metabolomic analysis shows an unusual accumulation of glutamine in the cells, indicating 
that uptake rates far surpass any flux through glutamine consuming pathways (Kourtidis 
and Conklin, unpublished data). It is possible that glutamine is used to take up or excrete 
other compounds through sym- or anti-port transporters, respectively. The exact nature of 
the anaplerotic and glutamine utilization pathways in HER2 positive breast cancer are 
currently under investigation in our lab. 
The synergistic action of HER2, PBP and NR1D1 allows cells carrying the HER2 amplicon to 
maintain a high flux rate through glycolysis and accumulate building blocks to sustain a 
high rate of cell proliferation. This might explain why therapies that target only HER2 are 
initially effective and result in the development of resistance. NR1D1 and PBP might be 
sufficient to drive the oncogenic metabolism once it is established. This is evidenced by the 
reversal of Herceptin resistance by FASN inhibition.  
This metabolic phenotype is reminiscent of Warburg’s original observation of aerobic 
glycolysis in cancer cells (Warburg 1956), except that the electrons do not end up in lactate. 
Metabolomic analysis indicates that overexpression of NR1D1 in MCF10A cells reduces 
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lactate levels by approximately 56 % (Baumann et al, unpublished data). The end result for 
the cancer cells are the same, if not more beneficial in the case of the “Warburg-like” 
metabolism we observed in HER2/neu-positive breast cancer cells. In the canonical 
Warburg effect lactate serves as an electron sink and as a means to regenerate NAD+, which 
allows for continued flux through glycolysis, but lactate is then excreted from the cells as a 
waste product. HER2/neu-positive breast cancer cells use fatty acids as an electron sink to 
regenerate electron acceptors while simultaneously generating building blocks needed for 
cell proliferation.  
Considering the movement of electrons in these cells provides a valuable frame of reference 
for understanding the metabolism of HER2/neu-positive breast cancer. All living organisms 
rely on the oxidation of energy rich compounds like glucose to fuel cellular processes like 
growth and proliferation. This is achieved by directing electrons from glucose through 
various steps toward a terminal electron acceptor, often oxygen, to create water. During this 
process the potential energy of these electrons can be used to fuel endergonic reactions. The 
carbon backbone of glucose is terminally oxidized to CO2 and excreted. Plants use water, 
CO2 and energy to produce glucose, completing the cycle. Of course this is an 
oversimplified version of the real picture but it helps to illustrate a point. The problem for 
any metabolizing cell can be described as one of electrons and their corresponding energy 
levels, the nature of the compound they are part of in any system at any given time is only 
important in terms of its reactivity and potential inhibitory effects on enzymes. In a complex 
organism each cell takes up electrons at a high energy level which need to be shuttled 
towards stable, lower energy compounds for the cell to be able to utilize their potential 
energy. In a homeostatic, non-proliferative setting, when oxygen can function as the 
terminal electron acceptor, this process is highly regulated and very efficient. One mole of 
glucose generates 36 moles of ATP, 6 moles of CO2 and 6 moles of H2O. All electrons are 
bound in stable non-reactive products that can freely diffuse out of the cell. In anaerobic 
conditions, for example in muscle tissue, the terminal electron acceptor can be pyruvate, 
which generates lactate. Lactate is then excreted from the cell and further metabolized in 
other organs. In a proliferative setting a growth signal will instruct certain cells to deposit 
electrons in an intermediate stable acceptor like fatty acids and other compounds needed to 
create a new cell. This is again a tightly controlled and highly efficient process that will 
eventually return to oxygen reduction once the growth signal is removed.  
In a situation where uncontrolled proliferation takes place because of chromosomal 
aberrations the cell needs to substantially increase its uptake of high energy electrons in the 
form of glucose. Most of them will end up in new cellular matter, which leaves little energy to 
be used by the cell for other processes. This creates a disconnection between electron uptake, 
energy usage and deposition of electrons in stable end products. One round of glycolysis will 
generate 4 electrons, 2 molecules of ATP and 2 molecules of pyruvate per molecule of glucose. 
The deposition of the electrons into pyruvate will generate a stable end product that can be 
excreted but leaves no carbons to accumulate new biomass for proliferation. Increasing the 
flux through glycolysis will yield an increase in usable energy and carbons that can be used by 
the cell but it also requires fast regeneration of electron acceptors. The best solution for this 
problem is to uncouple the terminal electron acceptor from the primary anabolic pathways 
that need to be carried out in a regulated concerted way. Increased flux through glycolysis to 
increase energy uptake is only feasible if electron acceptors can be regenerated quickly and if 
end products can be excreted or shuttled into other pathways to avoid negative feedback 
through product inhibition. The accumulation of one or more metabolites in cancer cells might 
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simply be a result of an energetic necessity: the transfer of electrons into stable intermediates 
that have only a minor inhibiting effect on their corresponding biosynthetic pathways. 
HER2/neu-positive breast cancer cells produce lots of fatty acids because their genetic 
program enables them to further shuttle the toxic fatty acids towards non-toxic, basically inert, 
triacylglycerides that are then stored in the cell. Palmitic acid, which has a strong inhibitory 
effect on acetyl-CoA carboxylase ǂ (ACACA), the rate-limiting step of fatty acid synthesis, 
never accumulate in these cells. The terminal electron acceptor in these cells is, for all practical 
purposes, acetyl-CoA.  
The stoichiometry of these processes does not come out even and it does not have to. 
Stoichiometry only works if we look at a well-defined chemical reaction with a starting point 
and an end point, which is not necessary if we consider metabolic flux as an ongoing process. 
If one particular product cannot be formed any more, the preceding substrate will accumulate 
and be diverted into other metabolic pathways. Depending on all the different reactions going 
on in the cell that require either energy or carbons, any excess electrons can just flow towards 
other lower energy states in compounds that can serve as a substitute for oxygen, for example, 
pyruvate. Despite the fact that in HER2/neu-positive breast cancer cells the majority of 
electrons are deposited in triglycerides, these cells still produce lactate. Lactate can be excreted 
from the cells and will then feed into the Cori Cycle, which will result in glucose production in 
the liver and subsequent glucose export into the bloodstream. This type of metabolism is 
hardly efficient in terms of energy usage but it is very resilient and robust and allows for 
consistent production of energy and cellular matter. This is reflected in the slow growth rate of 
HER2/neu-positive cancer cell lines in vitro. The HER2/neu-positive cell line BT474 has a 
doubling time of approximately 100 hours whereas the HER2 negative line MCF7 takes about 
29 hours for a population doubling. This seems counter-intuitive considering that HER2/neu-
positive breast cancer has a worse prognosis and decreased survival time, but it is intriguing to 
speculate that in the complex environment of a human body growth rate might be less 
important than robust survival and growth in all conditions. 
The accumulation of fat in HER2/neu-positive breast cancer cells raises other issues relating to 
the microenvironment, tumor growth and metastasis. By storing triglycerides these cancer 
cells store a vast amount of energy that is at the cells disposal if the environment of the cell 
changes. It is possible that these energy stores provide an advantage in case the cell enters a 
quiescent state or metastasizes to a new site as it will be less dependent on external energy 
sources if changes in metabolic regulation occur that allows the cells to switch to beta-
oxidation for energy production. Tumors that produce a lot of lactate and excrete it into the 
tumor microenvironment will have a severe impact on the physiology of the surrounding cells. 
Excess lactate accumulation acidifies the tumor microenvironment and results in NF-κB and 
Hif1ǂ activation which in turn results in angiogenesis and inflammation (reviewed in Allen & 
Jones 2011). This is likely to coincide with an increased influx of immune cells that will result 
in tumoricidal activity until the tumor is able to evade the immune response. In the case of 
HER2/neu-positive cells the efflux of lactate is decreased resulting in a less acidic tumor 
microenvironment, which might promote tumor immune evasion. 
4. A potential role for metabolism in the epigenetics of Her2/neu-positive 
breast cancer 
Epigenetic dysregulation is a well accepted contributing factor to tumorigenesis (Esteller 
2007). Many of the cofactors that are required for the establishment of epigenetic marks are 
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intermediates in the cellular metabolism. These include S-adenosylmethionine (SAM), 
NAD+, and acetyl-CoA. Changes in the concentrations as well as in the intracellular spatial 
distributions of these molecules can have a profound impact on the epigenetic status of the 
cells. Alterations in how these molecules interact with each other can also influence the 
epigenetic modifications. By taking what has been learned about changes in cancer 
metabolism we can generate new ideas that will lead to a better understanding of how the 
flux of electrons in HER2/neu-positive breast cancer ultimately affects its epigenome and 
thus gene expression (Figure 1). More on the basics of epigenetics and cancer can be found 
in many recent reviews (Portela & Esteller 2010; Jovanovic et al. 2010; Sharma et al. 2010). 
 
 
Fig. 1. The altered metabolism of HER-2/neu-positive breast cancer cells allows electrons 
from glucose to be deposited in triglycerides. Changes in levels of cofactors required for or 
affected by this process may have effects on epigenetic regulation. See text for details. 
4.1 Methylation 
Breast cancer, like all human cancers, is known to have differences in DNA methylation 
patterns (Esteller 2007; Ruike et al. 2010). During the development of the disease there is a 
global decrease in DNA methylation, also known as hypomethylation. However, 
concurrently there is an increase in CpG island (CGI) methylation at the promoters of tumor 
suppressor genes. Generally, genes important in apoptosis, metastasis, cell cycle regulation, 
angiogenesis and genes that encode non-coding RNAs (ncRNAs) are differentially 
methylated in breast cancer (Jovanovic et al. 2010). This improper methylation pattern 
begins in the primary tumor and increases upon metastasis, leading to alterations in gene 
expression (Feng et al. 2010). This change occurs in concert with an alteration in histone 
methylation, leading to a decrease in the expression of tumor suppressor genes in breast 
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cancer (Sharma et al. 2010). It appears that histone methylation levels are decreased in 
HER2/neu-positive breast cancer compared to other subclasses of breast cancer and may 
play a role in the poor prognosis of HER2/neu-positive tumors (Elsheikh et al. 2009). 
Alterations to one-carbon metabolism, specifically the methionine cycle, play a major role in 
all methylation reactions that occur in epigenetics. During the methionine cycle, dietary 
methionine is converted into SAM. SAM is then used as the methyl donor in various 
reactions inside the cell leaving S-adenosylhomocysteine (SAH) as a byproduct, which can 
be reconverted to methionine in a folate (vitamin B-12) dependent reaction (Mato et al. 
1997). Dietary reductions in folate have been linked to hypomethylation of both DNA and 
histones in liver diseases, the neurological development of embryos, as well as the 
development of both liver and colorectal cancer (Mato and Lu 2007; Greene, Stanier, and 
Copp 2009; Pogribny et al. 2004; van Engeland et al. 2003; Davis and Uthus 2003). 
Experimental evidence suggests that the tumor suppressor gene p53 is hypomethylated in 
mice with a folate deficiency, which results in decreased protein function as well as in an 
increased mutation rate (Kim et al. 1997; Liu et al. 2008). Work examining the direct role of 
SAM on the growth of cancer cells has also shown changes in methylation patterns. In rat 
models of hepatocarcinogenesis and in human prostate cancer xenografts, SAM treatment 
slows the growth of tumors and prevents new tumor growth (Pascale et al. 2002; Shukeir et 
al. 2006). It is believed that this effect occurs through increased methylation at the promoters 
of the protooncogenes, c-myc, c-Ha-ras, and c-K-ras (Simile et al. 1994). Taken together, 
these results from nutritional studies and from SAM treatment studies support the 
hypothesis that the availability of SAM can affect the epigenetic modifications of cancer 
cells. 
Methylation is also directly correlated with the redox potential inside the cell. Normal cells 
maintain a reducing environment inside the cytosol, whereas cancer cells develop a pro-
oxidant cytosolic environment (Cerutti 1985). Most of the intracellular reduction potential is 
due to the production of glutathione (GSH) which functions as the main cellular redox 
buffer. The ratio of GSH to its reduced form, glutathione disulfide (GSSG), is an important 
indicator of the intracellular redox state. In non-pathological states, GSSG levels approach 
almost zero (Schafer & Buettner 2001). Results from our lab indicate that there are 
alterations in the redox state in a HER2/neu-positive cell line compared to a normal breast 
epithelial line (Kourtidis & Conklin, unpublished data). Enzymes that contain redox 
sensitive amino acids such as cysteine are at particular risk of losing their catalytic activity in 
this environment. In fact many of the enzymes important in epigenetics are altered by the 
pro-oxidant state of the cancer cell (Hitchler & Domann 2009). 
The decreased levels of GSH found in many cancer cells can alter epigenetic patterns by 
affecting SAM levels. After SAM has donated its methyl group, SAH is converted into 
homocysteine. Homocysteine can then reenter the methionine cycle, or, as has been shown 
in a in a pro-oxidant environment, be shuttled into GSH synthesis (Mosharov et al. 2000). As 
homocysteine is shuttled away from the methionine cycle less SAM is generated, which 
results in a reduced supply of methyl donors for DNA methyltransferases (DNMTs) and 
histone methyltransferases (HMTs). This finding is confirmed when GSH is chemically 
depleted (Lertratanangkoon et al. 1997). This scenario is further exacerbated because the 
enzymes in the methionine cycle are redox sensitive and inactivated by oxidation (Hitchler 
& Domann 2009). DNMT and HMT also have conserved catalytic cysteine residues present 
in their active sites (Chen et al. 1991; Zhang et al. 2003). Oxidation of these residues impairs 
the function of the both the DNMT as well as the HMT, which will also influence epigenetic 
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methylation patterns (Hitchler & Domann 2009). Taken together, all of these factors 
illustrate how the altered metabolism in HER2/neu-positive breast cancer cells can 
influence epigenetic modifications of both DNA and histones and thus influence gene 
expression. 
4.2 Acetylation 
The importance of histone modifying enzymes like histone deacetylases (HDACs) in cancer 
is also becoming clearer (Jovanovic et al. 2010). Breast cancer is no different. As with histone 
methylation, there is a global decrease in acetylation in HER2/neu-positive breast cancer in 
comparison with other classes of breast cancer (Elsheikh et al. 2009). It is believed that the 
hypermethylated CGI of tumor suppressor promoters attract HDACs either directly, or 
indirectly through methyl binding proteins (MBPs) increasing the repressed state of these 
genes (Dalvai & Bystricky 2010). Very little is known about HDAC expression in 
HER2/neu-positive breast cancer, despite the fact that HDAC 1 and 3 are overexpressed in 
most breast cancers and the expression levels of HDACs 2,4,6 decrease as the cancer 
develops (Dalvai & Bystricky 2010). The significance of these changes of acetylation has not 
yet been established, but it is intriguing to speculate that the altered metabolism in 
HER2/neu-positive breast cancer cells changes the availability of important co-factors that 
are required for histone acetylation and deacetylation. 
The cofactor NAD+ and its reduced counterpart NADH play a major role in the movement 
of electrons in cells. The overall cellular ratio of NAD+/NADH effects the overall cellular 
redox environment, and alters the activity of various NAD+ dependent enzymes. When cells 
use aerobic glycolysis as their main energy generation pathway, there is an overall decrease 
in the NAD+/NADH ratio (Vander Heiden et al. 2009). We have noted that this 
phenomenon occurs in comparing NAD+/NADH ratios of HER2/neu overexpressing breast 
cancer cell lines to normal breast epithelial cells lines (Kourtidis & Conklin, unpublished 
data). 
Examining the effect of the decreased NAD+/NADH ratio in relation to cancer cells is in its 
infancy, however, its role in lifespan extension has been studied for many years in 
organisms from yeast to human (Imai et al. 2000; Anderson et al. 2003; Guarente 2005). 
Caloric restriction, specifically a glucose reduction, leads to an increase in life span in yeast 
and mammals (Guarente 2005). The extension in longevity occurs because of the increase in 
ratio of NAD+/NADH (Zhang & Kraus 2010). This shift is thought to inhibit the function of 
the sirtuins, a NAD+ dependent class of HDAC, leading to a decrease in their functional 
ability to deacetylate histones, as well as other protein targets such as transcription factors 
(Imai et al. 2000; Zhang & Kraus 2010). These two facts together potentially allow for some 
of the aberrant gene expression that occurs in HER2/neu-positive breast cancer cells 
displaying a Warburg-like physiology. 
Work in our lab has shown that the nuclear receptor NR1D1 plays a role in the proliferation 
and lipid production in HER2/neu-positive breast cancer cells (Kourtidis et al. 2010). 
NR1D1, which is overexpressed in HER2/neu breast cancer, functions as a transciptional 
repressor by recruiting HDAC3 to its target genes. Recent Chip-seq data from liver cells 
echoes this concept indicating that NR1D1 binds genes important in lipid synthesis and 
other metabolic pathways leading to a recruitment of HDAC3 (Feng et al. 2011). The exact 
effects of NR1D1 mediated transcriptional repression are likely to be tissue specific since 
gene expression data from HER2/neu-positive breast cancer cells shows NR1D1 dependent 
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upregulation of lipid synthesis genes. The mechanism of this phenomenon is likely to be 
indirect. These findings could indicate that the overall decrease in histone acetylation in 
breast cancer may be caused by overexpression of NR1D1 and widespread HDAC3 
recruitment. 
However, some genes like HER2/neu itself display increased acetylation which results in 
upregulated gene expression (Mishra et al. 2001). This leads to the conclusion that while 
there is a global decrease in histone acetylation, differential acetylation occurs in breast 
cancer cells compared to normal breast cells. The Warburg-like metabolism of HER2/neu-
positive breast cancer cells is likely to alter the availability and consumption of acetyl-CoA 
as a cofactor for acetylation and thus may influence acetylation patterns. There is not just a 
global decrease in histone acetylation, but also an alteration of histone modifications that 
lead to the expression of genes necessary for the survival and proliferation of the 
HER2/neu-positive breast cancer. The availability of acetyl-CoA can also have implications 
for other proteins that are acetylated, for example p53. The differential acetylation of 
transcription factors is another mechanism apart from histone acetylation, which illustrates 
how acetylation patterns can alter gene expression. 
5. Conclusion 
In HER2/neu-positive breast cancer, several genes are frequently co-amplified along with 
HER2. Recent evidence has shown that the co-amplified genes, NR1D1 and PBP, are 
required for HER2/neu-positive breast cancer cell survival. NR1D1 and PBP are important 
regulators of adipogenesis and their overexpression, functionally associated with PPARǄ, 
induces a Warburg-like metabolism that uniquely primes these cells for fat production and 
fat storage. HER2/neu-positive breast cancer cells store significantly more fats compared to 
HER2 negative breast cancer cells and normal human mammary epithelial cells. Since it is 
the synthetic process that is required for cell survival and not the amount of stored fats, 
disruption of fat synthesis induces apoptosis, whereas a similar decrease in fat stores 
through growth on alternative carbon sources does not. NR1D1 and PBP do not act through 
HER2 as knockdown of NR1D1 does not change HER2 transcript levels. HER2/neu-positive 
breast cancer cells are dependent on this type of metabolism as disruption of other 
pathways required for continued fatty acid synthesis results in apoptosis. This altered 
metabolism allows HER2/neu-positive breast cancer cells to shuttle electrons from glucose 
to neutral fat stores. The constant production of fatty acids allows the regeneration of NAD+, 
which in turn enables the cells to maintain a high flux rate through glycolysis. By storing 
those fatty acids in lipid droplets the cell avoids palmitate-induced cytotoxicity as well as 
feed-back inhibition of fatty acid synthase.  
The accumulation of fatty acids might confer an advantage to HER2/neu-positive cells in a 
state of quiescence or during metastasis, however, these possibilities warrant further 
investigation. It is however possible that cancer cells in general might just accumulate those 
metabolic intermediates that their genetic program allows them to synthesize as a means of 
regenerating NAD+ for continued energy production. For example, glioma cells have been 
reported to frequently express isocitrate dehydrogenase (IDH) mutations which result in the 
production of 2-hydroxy-glutarate from 2-oxo-glutarate. It is possible that this mutation 
poses an advantage simply because it enables the cells to use 2-hydroxy-glutarate as an 
electron sink, since the reaction consumes NADH, providing another parallel example of a 
potential Warburg-like physiology. 
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